Home News Tarsier Pharma receives FDA agreement under Special Protocol Assessment for Tarsier-04 Phase 3 Trial back to News
Alan Palestine, MD, director Center for Ocular Inflammation at the University of Colorado Department of Ophthalmology expresses optimism that the field is closer than ever to controlling inflammation without increasing the risk of glaucoma.
Topics: Press Coverage
1675 North Aurora Court
F731
Aurora, CO 80045
Administration: 720-848-2500
Appointments: 720-848-2020
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
